ClinicalTrials.gg
CompletedNCT07399288Updated Nov 2, 2026

Postherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk

An observational study in Herpes Zoster, Dementia and Postherpetic Neuralgia (PHN), sponsored by China Medical University Hospital. Completed at 1 site in Taiwan. Open to participants aged 40 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by China Medical University Hospital · Observational

How we know

Updated Nov 2, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
73,404
Ages
40 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Herpes Zoster with a site in Taiwan — 1 open to participants now, 2 under way, 1 of them phase 3. Herpes Zoster · Taiwan.

Started
2015
the only one that year
Observational
3 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
China Medical University Hospital

Among the 13 studies in Herpes Zoster with a site in Taiwan, this one is the only one that started in 2015, is one of 3 observational ones, and was the 13th registered.

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

1 of the 13 studies in Herpes Zoster with a site in Taiwan is open now. Recruiting first, the newest first:

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 40 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Herpes Zoster with a site in Taiwan, or all of them as a file.
02

Study summary

This retrospective observational cohort study uses de-identified electronic health record data from the TriNetX Global Collaborative Network to evaluate whether postherpetic neuralgia after herpes zoster is associated with an increased risk of incident dementia. Adults aged 40 to 120 years with incident herpes zoster between 1 October 2015 and 31 December 2024 are identified using diagnostic codes. Postherpetic neuralgia is defined by International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes B02.22 or B02.29 recorded between 90 and 365 days after the index herpes zoster date, and comparators have no such codes between 90 and 365 days after index. The primary analysis uses 1:1 propensity score matching and a 365-day landmark design, including only individuals alive and free of dementia at the landmark. Time-to-event analyses estimate hazard ratios for incident dementia and related outcomes.

Read the detailed description

Data source and study design This is a retrospective cohort study using de-identified electronic health record data accessed through the TriNetX platform. The primary analysis is conducted in the TriNetX Global Collaborative Network. Replication is performed in the TriNetX Asia Pacific (APAC) network as a geographic validation.

Population and index date Eligible individuals are aged 40 to 120 years and have an incident herpes zoster diagnosis (ICD-10-CM B02) recorded between 1 October 2015 and 31 December 2024, with a 3-year washout period free of herpes zoster before the index date. Baseline covariates are assessed up to 1 day before the index date.

Exposure definition Postherpetic neuralgia is defined by ICD-10-CM codes B02.22 or B02.29 recorded between 90 and 365 days after the index date. The comparator cohort includes individuals with incident herpes zoster and no record of B02.22 or B02.29 between 90 and 365 days after the index date. A prespecified stricter exposure definition requires at least two postherpetic neuralgia codes separated by at least 30 days.

Landmark design and follow-up The primary analysis uses a 365-day landmark after the index date. Only individuals alive and free of the specified outcome at the landmark enter the risk set. Follow-up starts at the landmark and continues until the first record of the outcome, death, or the last recorded fact in the patient's record, up to the date of data extraction.

Matching and analysis Cohorts are matched 1:1 using nearest neighbour propensity score matching with a caliper of 0.1. Balance is assessed using standardised mean differences. Time-to-event analyses use Kaplan-Meier methods and Cox proportional hazards models, reporting hazard ratios with 95% confidence intervals.

Outcomes The primary outcome is incident all-cause dementia defined by ICD-10-CM codes F01, F02, F03, or G30. Prespecified secondary outcomes include Alzheimer disease, vascular dementia, other or unspecified dementia, all-cause mortality, ischaemic stroke, and hip fracture. The Benjamini-Hochberg false discovery rate is applied to the six secondary outcomes only. A negative control outcome of acute appendicitis (ICD-10-CM K35) is included to assess residual bias.

Sensitivity and validation analyses Prespecified analyses include an alternative 730-day landmark, the stricter postherpetic neuralgia definition, additional adjustment for recorded zoster vaccination as a baseline covariate, and replication in the TriNetX APAC network using prespecified matching settings.

03

Conditions studied

  • Herpes Zoster
  • Dementia
  • Postherpetic Neuralgia (PHN)

Keywords

  • Landmark analysis
  • Propensity score matching
  • TriNetX
  • Alzheimer disease
  • Vascular dementia
  • Zoster vaccination
  • Negative control outcome
04

Who can participate

Ages eligible
40 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprises adults aged 40 to 120 years with incident herpes zoster identified in the TriNetX Global Collaborative Network from 1 October 2015 to 31 December 2024. Exposure groups are defined by the presence or absence of recorded postherpetic neuralgia diagnoses within 90 to 365 days after the index herpes zoster date. Follow-up for outcomes starts at a 365-day landmark after index among individuals alive and free of the outcome at the landmark. Replication analyses are performed in the TriNetX Asia Pacific (APAC) network.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 40 to 120 years with an incident herpes zoster diagnosis recorded between 1 October 2015 and 31 December 2024 in the TriNetX network.
  • A 3-year with no recorded herpes zoster diagnosis before the index date.
  • Eligible for analysis at the 365-day landmark after the index date, defined as being alive and free of the specified outcome at the landmark.

Exclusion criteria

Exclusion Criteria:

  • Any record of the specified outcome before the 365-day landmark.
  • Missing data elements required to define exposure status within the prespecified time window.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
73,404 participants (actual)
Patient registry
No

Groups and cohorts

  • Postherpetic neuralgia (PHN)

    Adults aged 40 to 120 years with incident herpes zoster between 1 October 2015 and 31 December 2024 who had a recorded postherpetic neuralgia diagnosis (ICD-10-CM B02.22 or B02.29) between 90 and 365 days after the index herpes zoster date. Follow-up begins at a 365-day landmark after index among individuals alive and free of dementia at the landmark.

    Other: Exposure: postherpetic neuralgia

  • Non-PHN comparator

    Adults aged 40 to 120 years with incident herpes zoster between 1 October 2015 and 31 December 2024 with no recorded postherpetic neuralgia diagnosis (ICD-10-CM B02.22 or B02.29) between 90 and 365 days after the index herpes zoster date. Follow-up begins at a 365-day landmark after index among individuals alive and free of dementia at the landmark.

Interventions

  • OtherExposure: postherpetic neuralgia

    This is an observational study and no treatment is assigned by the investigators. The intervention of interest is exposure status defined by recorded diagnoses of postherpetic neuralgia after herpes zoster, based on ICD-10-CM codes B02.22 or B02.29 within 90 to 365 days after the index herpes zoster date.

06

What researchers measure

Primary outcomes

  1. Incident all-cause dementia

    Incident all-cause dementia is identified using ICD-10-CM codes F01, F02, F03, or G30. Individuals with any record of dementia before the 365-day landmark are excluded from the risk set.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of dementia, death or the last recorded fact, up to the date of data extraction.

Secondary outcomes

  1. Alzheimer disease

    Incident Alzheimer disease is identified using ICD-10-CM code G30. Individuals with any record of Alzheimer disease before the 365-day landmark are excluded from the risk set.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of Alzheimer disease, death or the last recorded fact, up to the date of data extraction.

  2. Vascular dementia

    Incident vascular dementia is identified using ICD-10-CM code F01. Individuals with any record of vascular dementia before the 365-day landmark are excluded from the risk set.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of vascular dementia, death or the last recorded fact, up to the date of data extraction.

  3. Other or unspecified dementia

    Incident other or unspecified dementia is identified using ICD-10-CM codes F02 or F03. Individuals with any record of these diagnoses before the 365-day landmark are excluded from the risk set.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of other or unspecified dementia, death or the last recorded fact, up to the date of data extraction.

  4. All-cause mortality

    All-cause mortality is identified using the death indicator available within the TriNetX network.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of death or the last recorded fact, up to the date of data extraction.

  5. Ischaemic stroke

    Incident ischaemic stroke is identified using ICD-10-CM code I63. Individuals with any record of ischaemic stroke before the 365-day landmark are excluded from the risk set.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of ischaemic stroke, death or the last recorded fact, up to the date of data extraction.

  6. Hip fracture

    Incident hip fracture is identified using ICD-10-CM codes S72.0, S72.1, or S72.2. Individuals with any record of hip fracture before the 365-day landmark are excluded from the risk set.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of hip fracture, death or the last recorded fact, up to the date of data extraction.

Other outcomes

  1. Acute appendicitis (negative control outcome)

    Incident acute appendicitis is identified using ICD-10-CM code K35. Individuals with any record of acute appendicitis before the 365-day landmark are excluded from the risk set.

    Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of acute appendicitis, death or the last recorded fact, up to the date of data extraction.

07

Study locations

1 site
  • China Medical University Hospital
    Taichung, Taichung City 40447, Taiwan
08

References and documents

Publications

  • Stein E, Huser M, Amirian ES, Palchuk MB, Brown JS. TriNetX Dataworks-USA: Overview of a Multi-Purpose, De-Identified, Federated Electronic Health Record Real-World Data and Analytics Network and Comparison to the US Census. Pharmacoepidemiol Drug Saf. 2025 Sep;34(9):e70198. doi: 10.1002/pds.70198. PubMed 40915660 ↗
  • Warren-Gash C, Williamson E, Shiekh SI, Borjas-Howard J, Pearce N, Breuer JM, Smeeth L. No evidence that herpes zoster is associated with increased risk of dementia diagnosis. Ann Clin Transl Neurol. 2022 Mar;9(3):363-374. doi: 10.1002/acn3.51525. Epub 2022 Feb 16. PubMed 35170873 ↗
  • Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, Langan SM. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016 Jan;157(1):30-54. doi: 10.1097/j.pain.0000000000000307. PubMed 26218719 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) cannot be shared publicly because the TriNetX data are available only to subscribing organisations under licence agreements and governance controls. Investigators access de-identified records within the platform and are not permitted to download or redistribute line-level data. Researchers with access to TriNetX can reproduce the analysis using the cohort definitions and query parameters reported in the study.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2015 to primary completion in Oct 2026, 132 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2024 → Oct 2026 and completion Dec 2024 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
Oct 1, 2015
Primary completionActual
Oct 29, 2026was Dec 2024
CompletionActual
Oct 29, 2026was Dec 2024
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2024→Oct 29, 2026
Nov 2, 2026
Study completion
Dec 31, 2024→Oct 29, 2026
Nov 2, 2026
Enrollment
68786→73404
Nov 2, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameIncident all-cause dementiaFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of dementia, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of dementia, death or the last recorded fact, up to the date of data extraction.
Nov 2, 2026
Secondary outcomes
7 time frame changed
What changed in the outcomes
  • Time frameAlzheimer diseaseFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of Alzheimer disease, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of Alzheimer disease, death or the last recorded fact, up to the date of data extraction.
  • Time frameVascular dementiaFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of vascular dementia, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of vascular dementia, death or the last recorded fact, up to the date of data extraction.
  • Time frameOther or unspecified dementiaFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of other or unspecified dementia, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of other or unspecified dementia, death or the last recorded fact, up to the date of data extraction.
  • Time frameAll-cause mortalityFrom the 365-day landmark after the index herpes zoster date to the earliest of death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of death or the last recorded fact, up to the date of data extraction.
  • Time frameIschaemic strokeFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of ischaemic stroke, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of ischaemic stroke, death or the last recorded fact, up to the date of data extraction.
  • Time frameHip fractureFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of hip fracture, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of hip fracture, death or the last recorded fact, up to the date of data extraction.
  • Time frameother outcomeAcute appendicitis (negative control outcome)From the 365-day landmark after the index herpes zoster date to the earliest of the first record of acute appendicitis, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of acute appendicitis, death or the last recorded fact, up to the date of data extraction.
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Dec 31, 2024→Oct 29, 2026
    Study completion Dec 31, 2024→Oct 29, 2026
    Enrollment 68786→73404
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameIncident all-cause dementiaFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of dementia, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of dementia, death or the last recorded fact, up to the date of data extraction.
    Secondary outcomes 7 time frame changed
    What changed in the outcomes
    • Time frameAlzheimer diseaseFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of Alzheimer disease, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of Alzheimer disease, death or the last recorded fact, up to the date of data extraction.
    • Time frameVascular dementiaFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of vascular dementia, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of vascular dementia, death or the last recorded fact, up to the date of data extraction.
    • Time frameOther or unspecified dementiaFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of other or unspecified dementia, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of other or unspecified dementia, death or the last recorded fact, up to the date of data extraction.
    • Time frameAll-cause mortalityFrom the 365-day landmark after the index herpes zoster date to the earliest of death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of death or the last recorded fact, up to the date of data extraction.
    • Time frameIschaemic strokeFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of ischaemic stroke, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of ischaemic stroke, death or the last recorded fact, up to the date of data extraction.
    • Time frameHip fractureFrom the 365-day landmark after the index herpes zoster date to the earliest of the first record of hip fracture, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of hip fracture, death or the last recorded fact, up to the date of data extraction.
    • Time frameother outcomeAcute appendicitis (negative control outcome)From the 365-day landmark after the index herpes zoster date to the earliest of the first record of acute appendicitis, death, loss to follow-up, or 31 December 2024. → From the 365-day landmark after the index herpes zoster date to the earliest of the first record of acute appendicitis, death or the last recorded fact, up to the date of data extraction.
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07399288
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Oct 1, 2015
Primary completion
Oct 29, 2026
Completion
Oct 29, 2026
Last update
Nov 2, 2026

Study contacts

En-Bo Wu, MD
principal investigator · China Medical University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion